Epoqe Pharma
Epoqe Pharma is a pre-clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious cardiovascular diseases, with a focus on acute myocardial infarction (AMI). Their innovative approach utilizes natural heart rescue mechanisms, aiming to prevent death and disability caused by cardiovascular conditions worldwide.
Industries
health-care
medical
pharmaceutical
Nr. of Employees
small (1-50)
Patents
Products
Peptide analog therapeutic candidates for acute myocardial infarction
Preclinical-stage peptide analogs of a native peptide developed as therapeutic candidates to restore heart function and reduce infarct size in acute myocardial infarction and other acute or chronic cardiovascular diseases.
Peptide analog therapeutic candidates for acute myocardial infarction
Preclinical-stage peptide analogs of a native peptide developed as therapeutic candidates to restore heart function and reduce infarct size in acute myocardial infarction and other acute or chronic cardiovascular diseases.
Expertise Areas
- Preclinical pharmacology
- Peptide therapeutics
- Cardiovascular disease therapeutics
- In vivo ischemia and reperfusion models
Key Technologies
- Peptide therapeutic platforms
- In vivo ischemia/reperfusion animal models (minipig, rat)
- Cardiac functional assessment and infarct sizing
- Angiogenesis and vascular function assays
News & Updates
Press release from November 2023 about leadership update and IP strengthening.
Press release from July 2023 about funding received.
Press release from November 2023 about leadership update and IP strengthening.
Press release from July 2023 about funding received.